STK Markets is a diversified financial services provider operating in Australian and International equity and derivatives markets.
We offer our services to sophisticated / wholesale investors and institutional clients.
Overview
Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial.
Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations.
CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for immunocompromised individuals.
The key findings of CHAT include:
The mean maximum antibody levels (Cmax), measured using the Abbott AdviseDx SARS-CoV-2 antibody assay system for the convalescent plasma (n=11) and immunoglobulin (n=11) arms was 154.7 (+ 43.0) AU/mL and 685 (+ 224.1) AU/mL respectively – a fourfold increase over convalescent plasma.
The safety profiles of both convalescent plasma and immunoglobulin were as expected.
These trial results are incredibly important for many Australians unable to benefit from the current COVID-19 vaccines because of with underlying conditions such as immunodeficiency, certain cancers, and rare diseases..
“These results mark a significant milestone in our ongoing commitment to advancing healthcare and addressing the unmet needs of immunocompromised individuals whose responses to vaccination are less than optimal,” said Mr John Manusu, Aegros Cofounder and Managing Director.
“By announcing these results today, Aegros signals that it is an Australian manufacturer of plasma medicines that has achieved what many have failed to do; make and test a hyperimmune against SARS-CoV-2 to address a critical need amongst those who cannot benefit from a vaccine,”
“This result shows that Haemafrac®, our cutting-edge process of fractionation, not only meets the specifications required for an immunoglobulin product but can successfully provide a higher level of passive immunity against COVID-19 disease than convalescent plasma,” said Professor Hari Nair, Cofounder and Executive Chair Aegros.
Please see attached Aegros company press release for further information and details of the raising.
Kindly note that this offer is only available to wholesale or sophisticated investors.
Australia has two plasma fractionators and Aegros is one of them. This is the result of a grand plan to use Australian-invented technology to revolutionalise the plasma fractionation industry. Aegros was formed with the bold goal to make therapeutic plasma products more available to patients globally.
The $20B therapeutic plasma market is one of the least environmentally friendly & most wasteful industries. The HaemaFrac® reduces the environmental impact and reduces waste, doubling the volume of these lifesaving treatments and lowering costs and carbon footprint. Aegros is the disrupter to this 80-year-old oligopolistic industry.
Tungsten Metals Group Limited (TMG) is a producer of high- quality Ferrotungsten (FeW). It owns and operates the largest and most advanced processing plant outside of China, located in Vĩnh Bảo in Vietnam, 75km South East of Hanoi.
The plant can process up 4,000 tonnes of FeW per annum with production capacity of 16 tonnes per day. TMG buys Tungsten concentrate from global producers, ships to its plant and processes for sale with the pre-ordered off-take agreement.
This website may contain general financial product advice and does not constitute an offer or inducement to enter into a legally binding contract. It does not form part of the terms and conditions for STK Markets products or services. The information provided on this website is not intended as, nor is it a substitute for, personal or institutional financial services advice. As this website has been prepared without consideration of any specific client’s investment objectives, financial situation or needs, a financial advisor should be consulted before any investment decision is made. Readers acting on this information without first consulting an adviser do so entirely at their own risk.
Copyright © STK Markets Pty Ltd
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.